Nourshargh S, Williams T J
Department of Applied Pharmacology, National Heart and Lung Institute, London, England.
J Immunol. 1990 Oct 15;145(8):2633-8.
The role of neutrophil chemoattractant receptors in neutrophil stimulation in vitro is well established, however, the precise mechanisms underlying local neutrophil accumulation at inflammatory sites in vivo have not been defined. A fundamental question that remains open is whether chemoattractants act on the endothelial cell or the neutrophil to initiate the process of neutrophil migration in vivo. To address this question we have investigated whether neutrophil accumulation in vivo can occur if chemoattractant receptor occupancy is uncoupled from neutrophil stimulation. For this purpose we have used pertussis toxin (PT) as the pharmacologic tool. We have investigated the effect of in vitro pretreatment of rabbit neutrophils with PT on their responses in vitro and on their accumulation in vivo. Pretreatment of rabbit neutrophils with PT inhibited FMLP- and C5a-, but not PMA- induced increases in CD18 expression, neutrophil adherence, and degranulation in vitro. This pretreatment procedure with PT inhibited the accumulation of radiolabeled neutrophils in vivo in response to intradermally injected FMLP, C5a, C5a des Arg, leukotriene B4, IL-8, and zymosan in rabbit skin. Further, in contrast to the in vitro results, PT inhibited the PMA-induced 111In-neutrophil accumulation in vivo. Interestingly, pretreatment of neutrophils with PT also inhibited accumulation in response to intradermally injected IL-1, despite the reports that IL-1 lacks neutrophil chemoattractant activity in vitro. Although the experimental techniques used cannot distinguish the different stages of neutrophil migration involved, these results suggest that the accumulation of neutrophils induced by local extravascular chemoattractants in vivo depends on a pertussis toxin-sensitive receptor operated event on the neutrophil itself. Further, PMA and IL-1 may release secondary chemoattractants in vivo.
中性粒细胞趋化因子受体在体外对中性粒细胞刺激中的作用已得到充分证实,然而,体内炎症部位中性粒细胞局部聚集的精确机制尚未明确。一个悬而未决的基本问题是趋化因子在体内是作用于内皮细胞还是中性粒细胞来启动中性粒细胞迁移过程。为了解决这个问题,我们研究了如果趋化因子受体占据与中性粒细胞刺激解偶联,体内中性粒细胞是否还能聚集。为此,我们使用百日咳毒素(PT)作为药理学工具。我们研究了用PT体外预处理兔中性粒细胞对其体外反应及体内聚集的影响。用PT预处理兔中性粒细胞可抑制体外FMLP和C5a诱导的,但不抑制PMA诱导的CD18表达增加、中性粒细胞黏附和脱颗粒。这种PT预处理程序抑制了体内放射性标记的中性粒细胞对皮内注射的FMLP、C5a、C5a去精氨酸、白三烯B4、IL-8和酵母聚糖的聚集反应。此外,与体外结果相反,PT抑制了体内PMA诱导的铟-111标记中性粒细胞的聚集。有趣的是,尽管有报道称IL-1在体外缺乏中性粒细胞趋化活性,但用PT预处理中性粒细胞也抑制了对皮内注射IL-1的聚集反应。虽然所使用的实验技术无法区分中性粒细胞迁移的不同阶段,但这些结果表明,体内局部血管外趋化因子诱导的中性粒细胞聚集取决于中性粒细胞自身上一个对百日咳毒素敏感的受体介导事件。此外,PMA和IL-1可能在体内释放次级趋化因子。